Epirubicin and DTIC (EDIC) for Advanced Soft-Tissue Sarcomas
作者:
Massimo Lopez,
Silvia Carpano,
Luigi Di Lauro,
Patriziu Vici,
Ettore M S. Conti,
期刊:
Oncology
(Karger Available online 1991)
卷期:
Volume 48,
issue 3
页码: 230-233
ISSN:0030-2414
年代: 1991
DOI:10.1159/000226933
出版商: S. Karger AG
关键词: Chemotherapy;Epirubicin;Soft-tissue sarcomas
数据来源: Karger
摘要:
Fifty-six patients with measurable advanced soft-tissue sarcomas were treated with epirubicin, 90 mg/m2 intravenously on day 1, and DTIC, 250 mg/m2 intravenously on days 1–5, with the entire regimen repeated every 3 weeks. The overall response rate in 52 evaluable patients was 48% with 9 complete remissions. Noncardiac toxicity was limited predominantly to vomiting, alopecia and myelosuppression. Laboratory evidence of cardiotoxicity [≥20% decrease in left-ventricular ejection fraction (LVEF) from the baseline value] was observed in 4 out of 39 patients who had at least two determinations of LVEF, at a median dose of 1,305 mg/m2. Two patients had clinical congestive heart failure at cumulative dose of 1,440 and 1,620 mg/m2. These findings suggest that the combination of epirubicin and DTIC is an active regimen in soft-tissue sarcomas, and provide further evidence that epirubicin is a doxorubicin analogue with reduced cardiac toxicity, but preserved efficacy in this dise
点击下载:
PDF
(1927KB)
返 回